# Bromantane

Rating: Speculative — Little primary evidence yet: mechanism, anecdote or tradition
Type: Compound
Updated: 2026-08-06
Canonical: https://heretic.bio/articles/bromantane.html

> Bromantane is a Russian adamantane actoprotector developed in the 1980s and approved there as Ladasten for neurasthenia and asthenia. Its distinctive mechanism is genomic: it raises tyrosine hydroxylase expression to increase dopamine synthesis rather than forcing release or blocking reuptake, which is why effects reportedly persist after discontinuation. The key trial was a 728-patient Russian multicenter study; independent Western replication is essentially absent, and it is sold elsewhere only as a research chemical.

**Synonyms** : Bromantan, Bromontan, ADK-709, N-(4-Bromophenyl)adamantan-2-amine, Ladasten **CAS** : 87913-26-6 **Formula** : C₁₆H₂₀BrN (MW 306.25) **Class** : Adamantane derivative; Actoprotector (synthetic adaptogen); atypical CNS stimulant + anxiolytic

## Overview

Bromantane is a Russian-developed compound (1980s, Zakusov State Institute of Pharmacology, Moscow) classified as an **actoprotector** — a synthetic adaptogen designed to enhance physical and mental performance under extreme conditions (hypoxia, heat, fatigue, emotional stress) without increasing oxygen consumption or heat production. It was used in Soviet/Russian military, space, and sports medicine. Approved in Russia (as Ladasten) for neurasthenia/asthenia (persistent fatigue with anxiety). Not approved by FDA or most Western regulators; sold elsewhere as a research chemical. Banned by WADA as a stimulant/masking agent since 1997 (detected in 1996 Atlanta Olympics Russian athletes).

It stands out from typical stimulants (amphetamine, methylphenidate, cocaine) due to its **genomic mechanism** that upregulates dopamine biosynthesis enzymes rather than blocking reuptake or forcing release. Benefits often persist weeks after discontinuation. Low side-effect profile in clinical use; no observed tolerance or dependence in studies.

## History & Development

  * Developed in the 1980s as part of Soviet research into actoprotectors (pioneered by Prof. Vladimir Vinogradov’s team at the Military Medical Academy).
  * Related to earlier actoprotector **bemitil** (used by cosmonauts and athletes).
  * Soviet military use: Shortened recovery after physical exertion; tested in Afghanistan for marching fatigue and heat stress; used across Army, Air Forces, Navy for endurance, hypoxia resistance.
  * Post-USSR: Continued in sports medicine; 1996 Olympic doping incident → WADA ban.
  * Russian approval: ~1997–2009 as Ladasten for neurasthenia (F48.0 ICD-10). Large-scale trials supported safety/efficacy.
  * Immunomodulatory and anti-inflammatory properties noted in some studies.



**Lost Soviet Medical Knowledge angle** : Exemplifies pragmatic Soviet pharmacology focused on performance under duress with minimal exhaustion — contrasts with Western stimulant paradigms that often lead to crash and dependence.

## Chemistry & Structure

Adamantane “cage” linked to 4-bromoaniline. Structurally related to amantadine and memantine but pharmacologically distinct. Poor water solubility; oral bioavailability ~42%.

## Mechanism of Action (Deep Dive)

Primary effects stem from **indirect genomic actions** activating intracellular signaling (cAMP-, Ca²⁺-, phospholipid-dependent protein kinases, especially PKC and PKA) → increased transcription of key enzymes.

### Dopamine Synthesis Upregulation (Core MOA)

  * Rapid, pronounced, long-lasting upregulation of **tyrosine hydroxylase (TH)** and **aromatic L-amino acid decarboxylase (AADC/DDC)** expression in hypothalamus, striatum, VTA, nucleus accumbens, etc.
  * A single dose raised tyrosine hydroxylase expression 2–2.5× in rat hypothalamus within 1.5–2 hours.
  * Leads to increased _de novo_ dopamine biosynthesis and release (correlates with enzyme upregulation).
  * Not clinically relevant reuptake inhibition (requires very high in vitro concentrations, 50–500 μM). Differs sharply from amphetamines (release) or methylphenidate (DAT blockade).
  * Result: Steady dopaminergic enhancement without hyperstimulation, peripheral sympathomimetic overload, or rapid depletion.



### GABAergic Modulation (Anxiolytic Component)

  * Suppresses expression of GABA transporter genes (e.g., GAT3) → enhanced GABAergic transmission and availability in synapses.
  * Contributes to calm, non-sedating anxiolytic effects.



### Neurotrophins & Neuroprotection

  * Increases expression of **BDNF** and **NGF** (nerve growth factor) in striatum, hypothalamus, hippocampus (rat studies, 50 mg/kg single dose).
  * Activates mitogen-activated protein kinase cascade (ERK1/ERK2 and pERK).
  * Potential downstream effects: neuronal survival, plasticity, reduced inflammatory cytokines (IL-6, IL-17, IL-4 in models).
  * May contribute to lasting benefits post-discontinuation and possible anti-depressant-like or neuroprotective actions.



### Other

  * Possible mild serotonergic effects (increased 5-HT and 5-HIAA in some regions).
  * σ1 receptor agonism hypothesized (shared with amantadine/memantine) but not confirmed as primary for bromantane.
  * Anti-hypoxic and membrane-protective effects observed in physical performance studies.



**Key Distinction from Typical Stimulants** (literature quotes): \- No addictive potential, withdrawal, or functional exhaustion. \- No redundant sympathoadrenergic activation. \- Performance enhancement without hyperstimulation.

## Pharmacokinetics

  * **Onset** : 1.5–2 hours (oral)
  * **Duration** : 8–12 hours (oral)
  * **Half-life** : ~11.21 hours (humans); ~7 hours (rats, brain)
  * **Bioavailability** : ~42%
  * **Metabolism** : Cytochrome P450 (CYP) induction reported — potential for interactions with CYP-metabolized drugs (e.g., benzodiazepines, SSRIs, oral contraceptives). Metabolites may have anticholinergic profile at lower doses.
  * **Excretion** : Limited human data; animal studies show effects lasting ≥24h in some performance metrics.
  * **Routes** : Primarily oral (tablets/capsules/powder). Nasal/sublingual discussed anecdotally but lack clinical validation.



## Clinical Evidence

### Landmark Trial (Asthenia/Neurasthenia)

  * Multi-center Russian study: **728 patients** with asthenia.
  * Results: 76% physician-rated improvement (CGI-S 76%, CGI-I 90.8%). Benefits on fatigue, mood, motivation, and sleep persisted **1 month after discontinuation**.
  * Side effects: 3% (none serious); 0.8% discontinuation.
  * Also normalized sleep-wake cycle.



### Other Russian Studies

  * Improved attention, operational performance, sensomotor capabilities.
  * Immunomodulatory effects (T-cell subsets in social defeat depression model).
  * Physical work capacity: Superior to phenamine (amphetamine) in swimming/treadmill tests (mice/rats); 0.5–50 mg/kg; effects ≥24h; protects mitochondria in heart/skeletal muscle.
  * Heat protection, hypoxia resistance, cardiovascular effects (increased stroke/minute volume at reduced HR and peripheral resistance).
  * Toxicology (single dose, rats): Stimulant at 30–300 mg/kg; suppression at higher doses; LD50 very high (~1,750–8,100 mg/kg range in reports).



**Limitations** : Most data from Russian sources (1990s–2010s); limited independent Western replication. Strong internal consistency across studies.

## Effects & Benefits

  * **Fatigue/Asthenia** : Primary approved use; robust clinical support.
  * **Performance under stress** : Physical endurance, resistance to heat/hypoxia/fatigue without burnout.
  * **Cognitive/Motivational** : Subtle stimulation, increased motivation, focus with reduced errors (vs. amphetamines which increase speed but also errors). “Better-rested version of yourself.”
  * **Anxiolytic** : Calm energy without sedation or dependence (distinct from benzos or phenibut).
  * **Mood/Sleep** : Possible antidepressant-like (cytokine reduction, neurotrophins); normalizes sleep-wake.
  * **Other (preclinical)** : Increased sexual receptivity (dopaminergic); potential prolactin suppression; lasting dopaminergic sensitization (up to 1–2 months in some animal data).



**Onset of subjective effects** : Often gradual; anxiolytic may appear faster than full motivational effects (days 1–7).

## Practical Context

  * **Timing** : Morning only (insomnia risk if dosed later; effects 6–12h).
  * **Stacking notes** (theoretical): Pair with L-tyrosine (substrate for TH) 500–1000 mg. Potential synergy with other adaptogens or nootropics, but limited data.
  * **Forms** : Powder, capsules. Research chemical quality varies — demand batch-specific COAs.



**Upper limits** : Anecdotal up to 200 mg; diminishing returns and higher side-effect risk.

## Safety, Side Effects & Toxicology

**Favorable profile at therapeutic doses** : \- Common (∼3% in trial): Mild insomnia (timing-related), headache, irritability. \- Higher doses: Tension, restlessness, “wired but tired.” \- **Absent** : Tolerance, dependence, withdrawal, addiction potential, significant cardiovascular stimulation, hyperstimulation. \- **LD50** : Extremely high (mice ~8,100 mg/kg reported; rats ~1,750+ mg/kg). \- **hERG** : Predictive models sometimes flag; contradicted by actual cardiovascular data (increased output, reduced resistance). Not a clinical concern per available evidence. \- **CYP induction** : Clinically relevant — may reduce levels of co-administered CYP substrates. Avoid with MAOIs. \- **Other** : High doses in animals caused regurgitation, diarrhea, polyuria, mild hypothermia. No pro-hypoxic activity.

**Contraindications/Interactions** : Limited data; caution with CYP drugs, stimulants, or in cardiovascular patients (though some data support use in somatogenic asthenia with CV pathology).

**Special populations** : Not studied in pregnancy, pediatrics, etc. Research chemical status outside Russia means quality/safety responsibility on user.

## Comparisons

  * **Vs. Bemitil** (another actoprotector): Bromantane more dopaminergic/psychostimulant; bemitil more metabolic/anti-hypoxic.
  * **Vs. Amantadine/Memantine** : Shared family; bromantane stronger on dopamine synthesis upregulation.
  * **Vs. Typical stimulants** : No crash, tolerance, or peripheral overload; genomic vs. acute synaptic action.
  * **Vs. Modafinil/Eugeroics** : Different profile (anxiolytic + performance under duress vs. wakefulness promotion).



## Anecdotal Reports (Nootropics Communities)

Common themes: Subtle but effective motivation/energy for work/gym; reduced alcohol desire; variable emotional effects (some report mood swings); insomnia if dosed late; “clean” feel compared to other stimulants. Individual variation high; many praise lack of tolerance.

## Sourcing & Research Notes

Available as research chemical (powder/capsules/liquid). Prioritize vendors with third-party COAs. Not for human consumption in most jurisdictions. Quality control critical due to research status.

## Sources